Reference
[Please submit your publication]
|
Saito T, Oba T, Shimizu S, Asada A, Iijima KM, Ando K. Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262. Hum Mol Genet (2019) 28(18) 3062-3071
[
PubMed ID = 31174206
]
[
RRC reference
]
Tiwari P, Kumar A, Das RN, Malhotra V, VijayRaghavan K. A Tendon Cell Specific RNAi Screen Reveals Novel Candidates Essential for Muscle Tendon Interaction. PLoS One (2015) 10(10) e0140976
[
PubMed ID = 26488612
]
[
RRC reference
]
|
Off-target search result
cv : coefficient of variation
(0 mm hits / total siRNA count)
mm : mismatch
|
cv |
0mm |
1mm |
2mm |
3mm |
target transcript |
off target name |
100 |
459 |
0 |
0 |
0 |
NM_057732.3 |
CG8203-RA (Cdk5), mRNA |
0 |
0 |
5 |
2 |
2 |
NM_136002.1 |
CG15142-RA (CG15142), mRNA |
0 |
0 |
4 |
3 |
6 |
NM_001042817.1 |
CG4937-RB, transcript variant B (RhoGAP15B), mRNA |
0 |
0 |
4 |
3 |
6 |
NM_132955.1 |
CG4937-RA, transcript variant A (RhoGAP15B), mRNA |
0 |
0 |
4 |
3 |
2 |
NM_137098.2 |
CG8485-RA, transcript variant A (CG8485), mRNA |
0 |
0 |
4 |
3 |
2 |
NM_166043.1 |
CG8485-RD, transcript variant D (CG8485), mRNA |
0 |
0 |
4 |
3 |
2 |
NM_166041.1 |
CG8485-RB, transcript variant B (CG8485), mRNA |
0 |
0 |
4 |
3 |
2 |
NM_166042.1 |
CG8485-RC, transcript variant C (CG8485), mRNA |
0 |
0 |
4 |
2 |
7 |
NM_078666.2 |
CG8146-RA (Socs16D), mRNA |
0 |
0 |
3 |
2 |
9 |
NM_138020.2 |
CG3105-RA (CG3105), mRNA |
0 |
0 |
2 |
6 |
4 |
NM_168245.2 |
CG8110-RB, transcript variant B (syd), mRNA |
0 |
0 |
2 |
6 |
4 |
NM_079913.2 |
CG8110-RA, transcript variant A (syd), mRNA |
0 |
0 |
2 |
5 |
6 |
NM_168961.2 |
CG32451-RB, transcript variant B (SPoCk), mRNA |
0 |
0 |
2 |
4 |
2 |
NM_132908.2 |
CG4453-RA (Nup153), mRNA |
0 |
0 |
2 |
3 |
5 |
NM_169549.1 |
CG9351-RC, transcript variant C (flfl), mRNA |
0 |
0 |
2 |
3 |
5 |
NM_142047.1 |
CG9351-RA, transcript variant A (flfl), mRNA |
0 |
0 |
2 |
3 |
5 |
NM_169548.1 |
CG9351-RB, transcript variant B (flfl), mRNA |
0 |
0 |
2 |
3 |
3 |
NM_079771.1 |
CG11921-RA (fd96Ca), mRNA |
0 |
0 |
2 |
3 |
2 |
NM_079706.2 |
CG3412-RA (slmb), mRNA |
0 |
0 |
2 |
2 |
3 |
NM_176111.1 |
CG2049-RC, transcript variant C (Pkn), mRNA |
0 |
0 |
2 |
2 |
3 |
NM_176113.1 |
CG2049-RD, transcript variant D (Pkn), mRNA |
0 |
0 |
1 |
18 |
35 |
NM_079696.4 |
CG10498-RB, transcript variant B (cdc2c), mRNA |
0 |
0 |
1 |
18 |
35 |
NM_169916.1 |
CG10498-RA, transcript variant A (cdc2c), mRNA |
0 |
0 |
1 |
10 |
10 |
NM_132488.3 |
CG11727-RB, transcript variant B (CG11727), mRNA |
0 |
0 |
1 |
10 |
10 |
NM_167285.2 |
CG11727-RA, transcript variant A (CG11727), mRNA |
0 |
0 |
1 |
6 |
7 |
NM_141068.2 |
CG7597-RA, transcript variant A (CG7597), mRNA |
0 |
0 |
1 |
6 |
7 |
NM_168912.1 |
CG7597-RB, transcript variant B (CG7597), mRNA |
0 |
0 |
1 |
5 |
10 |
NM_167525.1 |
CG9802-RB, transcript variant B (Cap), mRNA |
0 |
0 |
1 |
5 |
10 |
NM_078650.2 |
CG9802-RA, transcript variant A (Cap), mRNA |
0 |
0 |
1 |
5 |
3 |
NM_176459.1 |
CG17228-RD, transcript variant D (pros), mRNA |
|